10173-56-5 Usage
Benzimidazole derivative
This compound is derived from benzimidazole, which is a heterocyclic aromatic organic compound.
Contains a benzimidazole ring
The compound has a benzimidazole ring in its structure, which is a five-membered and six-membered ring system.
Contains a chloroaniline moiety
The compound also has a chloroaniline group, which is a chlorine-substituted derivative of aniline.
Used in pharmaceutical research
2-(1H-benzimidazol-2-yl)-4-chloroaniline is commonly used as a building block for the synthesis of various drugs and drug candidates.
Potential biological activities and therapeutic applications
This compound has been studied for its potential biological activities and therapeutic applications, indicating that it may have potential as a pharmaceutical agent.
Potentially hazardous chemical
It is important to handle this compound with care as it is a potentially hazardous chemical.
Use by qualified professionals
2-(1H-benzimidazol-2-yl)-4-chloroaniline should be used only by qualified professionals in controlled laboratory settings to ensure safe handling and use.
Check Digit Verification of cas no
The CAS Registry Mumber 10173-56-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,0,1,7 and 3 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 10173-56:
(7*1)+(6*0)+(5*1)+(4*7)+(3*3)+(2*5)+(1*6)=65
65 % 10 = 5
So 10173-56-5 is a valid CAS Registry Number.
10173-56-5Relevant articles and documents
Benzimidazoquinazolines as new potent anti-TB chemotypes: Design, synthesis, and biological evaluation
Chakraborti, Asit K.,Dhameliya, Tejas M.,Jadhavar, Pradeep S.,Krishna, Vagolu Siva,Patel, Kshitij I.,Saha, Nirjhar,Sriram, Dharmarajan,Vaja, Maulikkumar D.
, (2020/03/31)
In search for new molecular entities as anti-TB agents, the benzimidazoquinazoline polyheterocyclic scaffold has been designed adopting the scaffold hopping strategy. Thirty-two compounds have been synthesized through an improved tandem decarboxylative nucleophilic addition cyclocondensation reaction of o-phenylenediamine with isatoic anhydride followed by further cyclocondensation of the intermediately formed 2-(o-aminoaryl)benzimidazole with trialkyl orthoformate/acetate. The resultant benzimidazoquinazolines were evaluated in vitro for anti-TB activity against M. tuberculosis H37Rv (ATCC27294 strain). Fourteen compounds exhibiting MIC values in the range of 0.4–6.25 μg/mL were subjected to cell viability test against RAW 264.7 cell lines and were found to be non-toxic (30% inhibition at 50 μg/mL). The active compounds were further evaluated against INH resistant Mtb strains. The most active compound 6x [MIC (H37Rv) of 0.4 μg/mL] and the compound 6d [MIC (H37Rv) of 0.78 μg/mL] were also found to be active against INH resistant Mtb strain with MIC values of 12.5 and 0.78 μg/mL, respectively.
